| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2024 , Vol 62 , Num 3
Topical apigenin as a promising therapeutic agent for psoriasis: Evaluating efficacy alone and in combination with clobetasol in an imiquimod-induced model of psoriasis in mice
1 Al-Nahrain University, College of Medicine, Department of Pharmacology, Baghdad, IraqDOI : 10.23893/1307-2080.APS6239 Viewed : 5246 - Downloaded : 1551 Psoriasis is an immune-mediated skin disease characterized by excessive growth and abnormal differentiation of keratinocytes that were treated initially with steroids which showed severe side effects for long-term use, so, medicinal plants are being explored as a potential alternative to identify new and effective agents with fewer adverse effects, such as apigenin which is investigated alone and in combination with clobetasol in this study for their anti-psoriatic activity on imiquimod-induced psoriasis on sixty male Albino mice divided into 6 groups. Group I is the control group, while the rest of the groups were induced psoriasis by Imiquimod (IMQ) for 6 consecutive days and administered different interventions for each group for 8 consecutive days including topical apigenin and apigenin/ clobetasol combination followed by a measurement of the clinical, histopathological, and laboratory effects and the findings demonstrated that apigenin effectively reduced the PASI score, enhanced the histopathology, downregulated the expression of TNF-?, IL-17, and VEGF, and significantly increased the IL10 level in mice"s skin tissue homogenate which indicate that Apigenin alone and in combination with clobetasol hold promise for the management of psoriasis, offering a potential alternative or adjunct to current therapeutic approaches. Keywords : psoriasis, apigenin, Imiquimod, Clobetasol, IL-10